

27

- 27 **Background**
28 The influence of pre-existing humoral immunity, inter-individual demographic factors, and vaccine-
- 29 associated reactogenicity on immunogenicity following COVID vaccination remains poorly understood. 29 associated reactogenicity on immunicity following COVID vacanisms in municipality and the entropy.
30 Methods
-
- 30 Methods
31 Ten-fold cross-validated least absolute shrinkage and selection operator (LASSO) and linear mixed
- 32 effects models were used to evaluate symptoms experienced during natural infection and following
- 33 SARS-CoV-2 mRNA vaccination along with demographics as predictors for antibody (AB) responses in
- 34 COVID+ participants in a longitudinal cohort study.
- 35 **COVID- participants in a longitudinal conort study.**
35 **Results**
- Sumbles 15 Sections Results
36 In previously infected individuals, AB were more durable and robust following vaccination when
- 37 compared to natural infection alone. Higher AB were associated with experiencing dyspnea during
- 38 natural infection, as was the total number of symptoms reported during the COVID-19 disease course.
- 39 Both local and systemic symptoms following 1^{st} and 2^{nd} dose of SARS-CoV-2 mRNA vaccines were.
- Ao predictive of higher AB after vaccination, as were the demographic factors of age and Hispanic ethnicity.
- 41 Lastly, there was a significant temporal relationship between AB and days since infection or vaccination. 41 Lastly, there was a significant temporal relationship between AB and days since infection or vaccination.

- 42 Conclusion
43 Vaccination in COVID+ individuals ensures a more robust immune response. Experiencing systemic and
- 44 Vacal symptoms post-vaccine is suggestive of higher AB, which may confer greater protection. Age and
- 45 Hispanic ethnicity are predictive of higher AB. 45 Hispanic ethnicity are predictive of higher AB.

46
47

 $\frac{1}{2}$ Keywords: Covid-19, protective antibodies, vaccine reactors: $\frac{1}{2}$

18 Introduction
19 The heterogeneous presentation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is 50 associated with inter-individual factors [1, 2], including age, biological sex, comorbidities, individual 51 susceptibility to the virus, exposure load, viral shedding, pre-existing binding or neutralizing antibodies 52 [3, 4], and pre-existing cross-reactive T cells [5-7]. Variability in these factors and their distinct 53 contributions to the individual immune response has made it difficult to generalize the clinical disease 54 course of SARS-CoV-2-infected individuals [1, 8]. Immunoassays have been used extensively throughout 55 the COVID-19 pandemic [9]. Their primary utility lies in characterizing the immune response following 56 vaccination, assessing viability for convalescent plasma donation, and acting as a population surveillance 57 tool [10, 11] though the most pressing work remains developing correlates for protection. Neutralizing 58 and binding titers remain well supported as protective markers [3, 12] regardless of natural infection or 59 vaccination, including a recent study [13] which associated increased binding and neutralizing antibodies 60 with an inverse risk for SARS-CoV-2 infection following mRNA-1273 (Moderna) vaccination. 61 61
62 62 Previous studies have evaluated change in peak post-vaccination antibody titers as a function of time
63 [14] and the relationship between quantitative antibodies and disease severity [15]. Additionally, there 64 is evidence suggesting that antibody titers in vaccinated, previously coronavirus disease 2019 (COVID-65 19) positive individuals $[16-19]$ can predict the degree of individual immune protection $[20]$. The aim of 66 this paper is to investigate relationships between sociodemographic factors, reactogenicity, and 67 immunogenicity following SARS-CoV-2 mRNA vaccination in previously SARS-CoV-2 infected participants.

68 This analysis addresses a gap in the current COVID-19 literature that may help elucidate how pre-

69 existing immunity and vaccine reactogenicity are associated with post-vaccination antibody titers (i.e., existing immunity and vaccine reactogenicity are associated with post-vaccination antibody titlers (i.e.,
70 humoral immunogenicity).

71 humoral immuno general in munos de la provincia de la provincia de la provincia de la provincia de la provi
2010 de marzo de la provincia de la provincia
2

 $\overline{3}$

83 prospective SARS-CoV-2 immunity study. Following the written informed consent process, participants 84 answered questions detailing their demographics, lifestyle habits, past medical history (including COVID-85 and COVID-19 infection symptoms. Blood samples were collected for serum and peripheral blood 86 mononuclear cell (PBMC) processing. Plasma was stored at -80°C and PBMCs were cryopreserved in

87 liquid N2 [22]. All participants agreed to sample banking for future research use. 88

88

89 Participants who were enrolled in the study between October 2020 – June 2021 and had a history of
90 COVID-19 were included in this analysis. mRNA vaccines (Pfizer (BNT162b2) and Moderna (mRNA-91 1273)) were the only options available [9] during the enrollment period and therefore most participants 92 received mRNA vaccines. Individuals who only received one dose of an mRNA vaccine or received the 93 Johnson & Johnson vaccine were excluded. Additionally, participants who were administered their 94 second dose of an mRNA vaccine >7 days after or <4 days before the recommended [23] number of days 95 after the first dose (21 days for Pfizer; 28 days for Moderna) were excluded in order to account for the

95 after the first dose (21 days for Pfizer; 28 days for Moderna) were excluded in order to account for the

96 temporal, transient nature of post-vaccine reactogenicity and the subsequent immune response in order
97 to best reflect the general population. Individuals with SARS-CoV-2 re-infection or breakthrough 98 infection were also excluded. All samples provided during the baseline visit and thereafter were 98 infection were also excluded. All samples provided during the baseline visit and thereafter were 99 included in this analysis.

101 Participants who received vaccines were instructed to return for two additional visits, where they
102 answered binary "Yes/No" questions in a survey about their symptoms following vaccination. Symptoms 103 were rated on a Likert scale, where a "0" indicated no symptoms and a "10" indicated the highest 104 symptom severity. They also provided blood samples, which were processed for PBMCs and plasma as 105 described above. Fourteen days after participants received Dose 2, we classified them as "fully 105 described above. Fourteen days after participants received Dose 2, we classified them as "fully"
106 december 2021

 107

107
108

108 Enzyme-Linked Immunosorbent Assay (ELISA)
109 SARS-CoV-2 ELISAs were performed using a well-described assay developed by the Icahn School of 110 Medicine at Mount Sinai [10, 11]. Briefly, 96-well plates were coated at 4 °C with SARS-CoV-2 spike 111 protein (2 µg/ml) solution and incubated overnight. Plates were blocked with 3% non-fat milk prepared 112 in PBS with 0.1% Tween 20 (PBST) and incubated at room temperature for 1h. After blocking, serial 113 dilutions of heat inactivated serum samples were added to the plates and incubated for 2h at room 114 temperature. Plates were washed three times with 0.1% PBST followed by addition of a 1:3,000 dilution 115 of goat anti-human IgG-horseradish peroxidase (HRP) conjugated secondary antibody (50µl) well and 116 incubated 1h. Plates were washed, 100 μl SIGMAFAST OPD (o-phenylenediamine dihydrochloride;) 117 solution was added to each well for 10 min and then the reaction was stopped by the addition of 50µl 118 per well of 3M hydrochloric acid. The optical density at 490nm (OD490) was measured using a Synergy 4 119 (BioTek) plate reader. The background value was set at an OD490 of 0.15 then discrete titers were 119 (BioTek) plate reader. The background value was set at an OD490 of 0.15 then discrete title titlers were w
The background value was set at an OD490 of 0.15 then discrete title title title title title title title title

5

120 reported in values of 1:100, 1:200, 1:400, 1:800, 1:1600, 1:3200, 1:6400, 1:12800, 1:25600, 1:51200,
121 1:102400, and 1:204800. The limit of detection was set at 1:100. 122

122
123

Statistical Analysis
124 SARS-CoV-2 antibody titers were log2-transformed before all statistical analyses. We utilized a 125 generalized additive model to model the bi-phasic change in antibodies over time, including the rate of 126 antibody decay following natural infection (after last positive SARS-CoV-2 test [LPT] result) and full 127 vaccination (\geq 14 days after the second mRNA vaccine dose) [24] by modelling antibody titers with the 128 smooth function number of days elapsed using a cubic regression with 3 knots and the fixed effect of 129 vaccination status (after natural infection/pre-vaccination and after full vaccination). We replicated the 130 above as a linear mixed-effects model (LMM), where we incorporated the same fixed effects but 131 included participants as a random-intercepts effect to control for individual differences. The rates of log-132 transformed antibody titer decay along with the limit of detection of our assay were used to estimate 133 the number of days that the antibodies remain detectable after both natural infection and full the number of days that the antibodies remain detectable after both natural infection after both natural infection and full inf

135
135

135
136 136 Ten-fold cross-validated least absolute shrinkage and selection operator (LASSO) models were employed
137 as a feature-selection and regularization technique. The LASSO models were tuned to select the simplest 138 model within one standard error of the lowest value root-mean-square error accuracy metric that 139 included at least two predictors (Supplementary Table 1). Four LASSO models with identical 140 demographic variables were constructed while controlling for time or days since LPT, 1st dose, or 2nd 141 dose, respectively, including: 1) the effect of infection symptoms on the antibody response post-142 infection, 2) the effect of infection symptoms on the antibody response post full vaccination, 3) the 143 effect of dose 1 vaccine symptoms on the antibody response post full vaccination, and 4) the effect of 143 effect of dose 1 vaccine symptoms on the antibody response post full vaccination, and 4) the effect of

160 Characteristics of the Study Population

161 Demographic characteristics are detailed in Table 1. Thirty-three participants were included in our post

162 infection cohort. The median number of days since LPT to entry into the study was 101 days. For the

163 post dose 1 and post dose 2 analysis, we included 49 and 48 participants, respectively. 163 post dose 1 and post dose 2 analysis, we included 49 and 48 participants, respectively.

164
165

165 Symptoms Reported Following Infection and Vaccination
166 The highest reported symptom during the vaccine-naïve COVID-19 course was fatigue (63%) (Table 2).

167 Other highly reported symptoms included anosmia (55%), congestion (53%), and myalgias/muscle aches 167 other highly reported symptoms included anosmia (55%), congestion (53%), and my algebra \sim

171
172

172 In Previously Infected Individuals, Antibody Titers Are More Robust Following Full-Vaccination as
173 Compared to Post Natural Infection

174 We found that there was a more robust antibody response immediately following full vaccination

175 (Figure 1C) when compared to the antibody response following natural infection (estimate = 4.117, $t =$

176 12.950, $p = 0.001$ (Figure 1B), where peak log_2 antibody titers where greater in the vaccination with

177 prior infection (14.517) than in natural infection (9.217). This is illustrated in Figure 1A, where natural

178 infection and post-full vaccination titers were included in a bi-phasic model to show longitudinal

179 antibody responses. Infected individuals had a slower rate of antibody titer decay (-0.010 vs -0.015 log

180 per day), though this effect was small (estimate = -0.005, $t = 2.351$, $p = 0.020$). Our linear model also

181 predicted that antibody titers remain detectable for a longer period of time after full vaccination (535)

182 days) compared to natural infection alone (404 days), using the respective rates of antibody decay and

183 the limit of detection for our assay. Additional LMMs confirmed our findings that antibody titer declined

184 faster following full vaccination than in natural infection (estimate = -0.006, $F = 11.238$, $p \le 0.001$). Of

185 note, the combination of natural infection followed by vaccination, or so-called "hybrid immunity",

186 elicits a more durable antibody response than natural infection alone (estimate = 4.138, $F = 794.623$, $p <$

187 0.0001), as log₂ antibody titers were predicted to remain detectable for a longer period of time following

188 vaccination (550 days) than natural infection (464 days). 189

189
190

190 Days Elapsed and Symptoms Reported During Infection Influence Antibody Titers

191 As shown in Table 3, difficulty breathing during infection (estimate = 1.590, $F = 5.684$, $p = 0.024$) and
192 days elapsed since LPT (estimate = -0.006, F = 9.912, $p = .004$) were significant main effects in predicting 193 antibody titers following natural infection. Post-hoc testing confirmed that antibody titers were elevated 193 and titular infection. Post-hoc testing natural infection. Post-hoc testing communications were elected that an
194 and individuals who experienced difficulty breathing (z = 2.612; p = 0.009). 194 in individuals who experienced difficulty breathing (z = 2.612; $p = 0.669$).
195 195
196 196 When modeling demographics and symptoms at infection to predict the antibody response after full
197 vaccination, we found that days elapsed since full vaccination (estimate = -0.014; $F = 258.176$; $p <$ 198 0.0001), age (estimate = 0.018; $F = 6.000$; $p = 0.019$), and ethnicity (Hispanic) (estimate = 0.456; $F =$ 199 5.265; $p = 0.018$) were significant main effects, though no categorical variables were significant after 199 5.265; p = 0.018) were significant main effects, though no categorical variables were significant after 200 post-hoc testing. 201
202 202 Symptoms Following Vaccination Are Predictive of Higher Antibody Titers After Full Vaccination
203 Local and systemic symptoms following 1st dose of SARS-CoV-2 mRNA vaccines were predictive of higher 204 antibody titers after full vaccination. As seen in Table 3, the results of the LMM show that days elapsed 205 since full vaccination (estimate = -0.014, $F = 262.855$, $p < 0.0001$), chills (estimate = 0.541; $F = 4.915$; $p =$ 206 0.032), injection site redness (estimate = 1.243; F = 4.330; p = 0.044), age (estimate = 0.021; F = 6.960; p 207 = 0.012), and ethnicity (estimate = 0.562, $F = 4.583$, $p = 0.038$) were significant. Following post-hoc 208 Tukey testing on the significant categorical main effects, we found that injection site redness ($z = 2.081$, 209 $p = 0.038$) and ethnicity (Hispanic) ($z = 2.382$, $p = 0.017$) were significant, while the main effect of chills 209 p = 0.038) and ethnicity (Hispanic) (z = 2.382, p = 0.017) were significant, while the main effect of chills
210 vas not. 211
211 211
212 We also examined demographics and symptoms reported during the 2nd dose of SARS-CoV-2 mRNA
213 vaccination and their effect on the antibody response after full vaccination. Days since full vaccination

214 vaccination and their effect on the antibody response after function and the construction response to $\frac{1}{2}$ 214 (estimate = 0.014; F = 259.745; p < 0.0001; age (estimate = 0.025; F = 7.052; p = 0.009; identifying as

215 Hispanic (estimate = 0.609; $F = 6.683$; $p = 0.013$), fever (estimate = 0.839; $F = 11.154$, $p = 0.002$), and
216 influenza vaccination (estimate = -0.475; $F = 4.405$; $p = 0.042$) were observed to be significant. Fever 217 and ethnicity (Hispanic) were found to be statistically significant ($z = 3.016$, $p = 0.003$; $z = 2.735$, $p = 1.42$ 218 and 0.006, respectively) following post-hoc testing, though influenza vaccination was not. 218 0.006, respectively) following post-hoc testing, though influenza vaccination was not. 219
220 220 The Number of Symptoms During Infection Result in Higher Peak Antibody Titers Post Full-Vaccination
221 As shown in Figure 2, the number of symptoms reported during infection significantly predicted peak 222 antibody titers after full vaccination (estimate = 0.10, $t = 2.10$, Pearson's $r = 0.296$; $p = .041$). Additional 223 linear models were conducted for the number of symptoms reported as a function of demographics, 224 where we found that the number of symptoms self-reported during infection was significantly 225 influenced by self-identifying as White (estimate = 4.679, $t = 2.153$, $p = 0.037$). No other demographic 225 influenced by self-identifying as white (estimate = 4.679, t = 2.159, p = 0.037). No other demographic
226 in was significant. 226 was significant. 227
228 228 **Discussion**
229 The goal of this study was to investigate the role of demographics, pre-existing immunity, and 230 symptomatology following infection and vaccination to ascertain whether they independently or 231 collectively are associated with immunogenicity following mRNA vaccination for COVID-19 in individuals 232 previously infected with SARS-CoV-2. Our results demonstrate higher durability and robustness of 233 antibody titers despite a faster rate of antibody decay following vaccination, which supports previously 234 reported findings [31] for SARS-CoV-2 mRNA vaccines. Unsurprisingly, our results also demonstrate that 235 a larger temporal gap between an individual's LPT and/or date of vaccination predict decline of antibody external gap between an individual gap between an individual decline of vaccination predict decline of an
236 a latters over time. 237 titers over time.
237

238 Following infection alone, we found that the number of symptoms reported and difficulty breathing
239 Auring the COVID-19 course were predictive of higher antibody titers. This result supports existing 240 evidence [32, 33] that individuals who report a more severe or symptomatic SARS-CoV-2 infection have 241 bigher peak titers than asymptomatic individuals. Our data also support higher peak antibody titers 242 following vaccination with increasing age [32, 34]. The possible relationship between the antibody titer 243 post-vaccination and vaccine reactogenicity is largely unknown. Given that strength of the antibody 244 post-vace was shown to correlate with disease severity in patients with COVID-19, we hypothesized that 245 more prominent post-vaccination adverse reactions might be associated with a stronger immune 246 response. After receiving dose 1 of either Pfizer or Moderna's COVID-19 vaccine, the local symptom of 247 injection site redness was found to be significantly predictive for higher antibody titers following full 248 vaccination and could be an indicator of the early and more prominent immune response. Interestingly, 249 after dose 2 we found that fever was significantly predictive for higher antibody titers following full 250 vaccination, though it should be noted that asymptomatic individuals mounted robust immune extend that it shows the noted that as well.
251 vaccinations as well. 251 responses as well.
252

252 253 Most critically, our analysis demonstrates that in previously infected individuals, SARS-CoV-2 mRNA
254 vaccines result in a more robust antibody response than that following infection alone. Indeed, in 255 individuals with "hybrid immunity", antibody titers peak following full vaccination at 4-fold higher than 256 those following naturally acquired immunity and appear to persist at detectable levels for >500 days 257 following vaccination. One explanation for this increased response could be the presence of pre-existing 258 memory T and B cell responses developed during natural infection. These cells might enhance a 259 secondary immune response following vaccination similar to that of a booster immunization. In addition 260 to bolstering the current CDC recommendations [35] that individuals previously infected with SARS-CoV-261 2 receive vaccination, our results provide additional, longitudinal support for this measure. In addition 261 2 receive vaccination, our results provide additional, longitudinal support for this measure. In addition

11

- 263 response [38, 39], which is vitally important as SARS-CoV-2 continues to produce variants capable of
- 264 immune evasion, such as Delta (B.1.617.2) and Omicron (B.1.1.529) [40]. 264 immune evasion, such as Delta (B.1.617.2) and Omicron (B.1.1.529) [40].

265
266 266 Current evidence supports a stronger reactogenic profile (both systemic and local) following the first
267 vaccine dose in previously infected individuals [41, 42], though it is worth noting that the median time 268 between COVID-19 to the first dose of vaccine in the studies cited above was either not reported or was 269 only 2.9 months. In our cohort, there is considerable variability between participants in days elapsed 270 from LPT to time of vaccination (1st dose median = 99 days; 95% CI = 72-159 days; 2nd dose median = 271 127 Days; 95% CI = 93-180 days). Given current knowledge regarding antibody decline, it is reasonable 272 to posit that a longer temporal gap between SARS-CoV-2 infection and vaccination may have resulted in 273 a more reactogenic response to the 2^{nd} dose of vaccine when compared to participants who had shorter 274 intervals between infection and vaccination as noted in the studies described above. 275 275
276 276 Previous work [43] examining the relationship between SARS-CoV-2 vaccine reactogenicity and
277 Immunogenicity has been limited by assay type (i.e., semi-quantitative assays) and only deigned to 278 measure immunity immediately following vaccination. Another group [44] conducted a survey to assess 279 reactogenicity of COVID-19 vaccines and found that previous infection was associated with an increased 280 risk of reporting any side effect. They also found that mRNA vaccines seemed to produce milder, less 281 frequent systemic side effects but more local reactions in comparison to vector vaccines (i.e., Oxford 282 Astra Zeneca AZD1222), which are consistent with our findings following the $1st$ dose. To our 283 knowledge, we are the first to examine predictors of reactogenicity and immunogenicity following SARS-284 CoV-2 vaccines in participants with prior COVID-19. 285

 12

 3099 group was further limited by the study timeline, as the first SARS-CoV-2 vaccination became available study timeline, as the first SARS-CoV-2 vaccination became available study of \sim

310 shortly after enrollment began and therefore limited the number of individuals we were able to follow 312 recent work has demonstrated that higher binding antibodies correlate to higher neutralizing antibodies 313 [13], expansive, multi-center longitudinal studies are needed. An ideal analysis would consist of a 314 multivariate analysis of reactogenicity, demographics, and quantitatively characterized antibody, B-cell 315 and T-cell responses, as immune protection seems to be contingent on all three tiers of the immune 316 response [50]. Further, some of the predictors used in our statistical analysis were found to be 317 significant in one test but not in post-hoc tests. Large, longitudinal studies are required to confirm a 318 significant group difference, but the predictors utilized herein should be included in future analyses. 319 Our bivariate analysis of symptoms experienced following the 1st and 2nd doses failed to demonstrate 320 that individual symptoms can influence peak antibody titers following full vaccination. The same was 321 true for race and ethnicity, which were not found to be significantly predictive for peak titers over time, 322 though we contend that this is because these models failed to control for individual differences, or 323 intercepts, to account for between-subjects' variability. 324 324
325

325 In conclusion, this work supports vaccination in COVID-19+ individuals to assure the most robust
326 Immune response possible. A combination of systemic and local symptoms is predictive of higher 327 antibody titers, which may correlate to a higher degree of protection. While more work is needed to 328 understand the role of antibodies against SARS-CoV-2 infection and breakthrough infection, particularly 329 in the age of boosters and variants capable of immune escape, repeating this type of analysis at the 330 population level will be critical in providing individual recommendations for future vaccine measures.

330 population level will be critical in providing individual recommendations for future vaccine measures.

14

- 331 Funding
332 This work is part of the PARIS/SPARTA studies funded by the NIAID Collaborative Influenza Vaccine
- 333 Innovation Centers (CIVIC) contract 75N93019C00051. 333 Innovation Centers (CIVIC) contract 75N93019C00051.
-

334
335

335 Acknowledgements
336 We express our sincerest gratitude to our intellectually curious and willing study participants for

337 donating their blood and time to this study. We also thank the core research team that have made this

- 338 study logistically possible, including Margaret Roach, Elizabeth Varghese, Celeste Sanchez, Ailet Reyes,
- 339 and the entire team of phlebotomists at the University of Miami's Clinical Translational Research Site. 339 and the entire team of phlebotomists at the University of Miami's Clinical Translational Research Site.
- 340
341

341 Conflicts of Interest
342 The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 343 serological assays (U.S. Provisional Application Numbers: 62/994,252, 63/018,457, 63/020,503 and 344 63/024,436) and NDV-based SARS-CoV-2 vaccines (U.S. Provisional Application Number: 63/251,020) 345 which list Florian Krammer as co-inventor. Patent applications were submitted by the Icahn School of 346 Medicine at Mount Sinai. Mount Sinai has spun out a company, Kantaro, to market serological tests for 347 SARS-CoV-2. Florian Krammer has consulted for Merck and Pfizer (before 2020), and is currently 348 consulting for Pfizer, Third Rock Ventures, Seqirus and Avimex. The Krammer laboratory is also 349 collaborating with Pfizer on animal models of SARS-CoV-2.

- 350
- 350
351 351 All other authors declare that they have no known competing financial interests or personal
352 Felationships that could have appeared to influence the work reported in this paper.
- 352 relationships that could have appeared to influence the work reported in this paper.
-

377 in humans. Nature Medicine 2020; 26:1033-6.

- 378 11. Stadlbauer D, Amanat F, Chromikova V, et al. SARS-CoV-2 Seroconversion in Humans: A Detailed
379 Protocol for a Serological Assay, Antigen Production, and Test Setup. Curr Protoc Microbiol 2020;
- 379 Protocol for a Serological Assay, Antigen Production, and Test Setup. Curr Protoc Microbiol 2020;
-
- 380 57:e100.
381 12. Feng S, Phillips DJ, White T, et al. Correlates of protection against symptomatic and asymptomatic
- 382 SARS-CoV-2 infection. Nature Medicine 2021; 27:2032-40.
- 383 13. Gilbert PB, Montefiori DC, McDermott AB, et al. Immune correlates analysis of the mRNA-1273
- 384 COVID-19 vaccine efficacy clinical trial. Science; 0:eab3435.
- 385 14. Crawford KHD, Dingens AS, Eguia R, et al. Dynamics of Neutralizing Antibody Titers in the Months
- 386 After Severe Acute Respiratory Syndrome Coronavirus 2 Infection. J Infect Dis 2021; 223:197-205.
- 387 15. Nagura-Ikeda M, Imai K, Kubota K, et al. Clinical characteristics and antibody response to SARS-CoV-2
- 388 spike 1 protein using VITROS Anti-SARS-CoV-2 antibody tests in COVID-19 patients in Japan. J Med
- asset i protein using Vital using VITROS Anti-SARS-Cover-2 anti-SARS-Cover-2 anti-SARS-Cover-2 patients in Japan. J
1989 Microbiol 2021; 70:001291.
- 389 Microbiol 2021; 70:001291.
390 16. Callegaro A, Borleri D, Farina C, et al. Antibody response to SARS-CoV-2 vaccination is extremely
- 391 vivacious in subjects with previous SARS-CoV-2 infection. J Med Virol 2021; 93:4612-5.
- 392 17. Lozano-Ojalvo D. Camara C. Lopez-Granados E. et al. Differential effects of the second SARS-CoV-2
- 393 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered individuals. Cell Rep 2021; 393 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered individuals. Cell Rep 2021;
-
- 394 36:109570.
395 18. Mungmunpuntipantip R, Wiwanitkit V. Antibody response to SARS-CoV-2 vaccination, previous
- 396 SARS-CoV-2 infection, and change to single-dose vaccination. J Med Virol 2021; 93:6474.
- 397 19. Hervé C, Laupèze B, Del Giudice G, Didierlaurent AM, Tavares Da Silva F. The how's and what's of
- 398 vaccine reactogenicity. npj Vaccines 2019; 4:39.
- 399 20. Salazar E, Christensen PA, Graviss EA, et al. Significantly Decreased Mortality in a Large Cohort of
- 400 Coronavirus Disease 2019 (COVID-19) Patients Transfused Early with Convalescent Plasma Containing $\mathcal{A}^{\text{max}}(\mathcal{A}^{\text{max}})$ patients Transformation \mathcal{A}^{max}

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2022.04.05.22273450;](https://doi.org/10.1101/2022.04.05.22273450) this version posted April 6, 2022. The copyright holder for this preprint

-
- 1.12 High-Titer Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Protein IgG. Am J
402 Pathol 2021; 191:90-107.
- 402 Pathol 2021; 191:90-107.
403 21. Tsang JS, Dobaño C, VanDamme P, et al. Improving Vaccine-Induced Immunity: Can Baseline Predict
- 404 Outcome? Trends in Immunology 2020; 41:457-65.
- 405 22. HANC. Cross-Network PBMC Processing Standard Operating Procedure, 2018:1-45.
- 406 23. CDC. Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized
- 406 23. CDC. Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized
- 407 in the United States. 2022.
408 24. R Development Core Team. R: A language and environment for statistical computing. R Foundation
- 409 for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing 2021.
- 410 at Statistical Computing. 25. Wood SN. Stable and efficient multiple smoothing parameter estimation for generalized additive
- 411 models. Journal of the American Statistical Association 2004; 99:673-86.
- 412 ag. Kuhn M. caret: Classification and Regression Training. R Package. 6.0-89 ed, 2021.
- 413 27. Friedman JH, Trevor; Tibshirani, Robert Regularization Paths for Generalized Linear Models via
- 414 Coordinate Descent. Journal of Statistical Software 2010; 33(1):1-22.
- 415 28. Pinheiro J BD, DebRoy S, Sarkar D, R Core Team. nlme: Linear and Nonlear Mixed Effects Models. R
- 111 28. Pinheiro J BD, Debroy S, Sarkar B, R Core Team. _nlm. Linear and Nonclear Mixed Effects Models. R
416 package version 31-152, 2021.
- 416 package version 31-152, 2021.
417 29. Torsten H BF, Westfall P. Simultaneous Inference in General Parametric Models. Biometric Journal 417 29. Torsten H BF, Westfall P. Simultaneous Inference in General Parametric Models. Biometric Journal
-
- 2008; 50:346-63.
419 30. Wickham H. ggplot2: Elegant Graphics for Data Analysis. New York, 2016.
- 420 31. Levin EG, Lustig Y, Cohen C, et al. Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine
- 421 over 6 Months. New England Journal of Medicine 2021; 385:e84.
- 422 32. Röltgen K, Powell AE, Wirz OF, et al. Defining the features and duration of antibody responses to
- 423 SARS-CoV-2 infection associated with disease severity and outcome. Sci Immunol 2020; 5. 423 SARS-CoV-2 infection associated with disease severity and outcome. Sci Immunol 2020; 5.

- 424 33. Gudbjartsson DF, Norddahl GL, Melsted P, et al. Humoral Immune Response to SARS-CoV-2 in
425 Leeland. New England Journal of Medicine 2020; 383:1724-34.
-
- 426 34. Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months
- 427 after infection. Science 2021; 371.
- 428 35. CDC. Science Brief: SARS-CoV-2 Infection-induced and Vaccine-induced Immunity. 2021.
- 429 36. Hall VJ, Foulkes S, Charlett A, et al. SARS-CoV-2 infection rates of antibody-positive compared with
- 430 antibody-negative health-care workers in England: a large, multicentre, prospective cohort study
- 431 (SIREN). Lancet 2021; 397:1459-69.
- 432 37. Sheehan MM, Reddy AJ, Rothberg MB. Reinfection Rates Among Patients Who Previously Tested
- 433 Positive for Coronavirus Disease 2019: A Retrospective Cohort Study. Clin Infect Dis 2021; 73:1882-6.
- 434 38. Regev-Yochay G, Amit S, Bergwerk M, et al. Decreased infectivity following BNT162b2 vaccination: A
- 435 prospective cohort study in Israel. The Lancet Regional Health Europe 2021; 7.
- 436 39. Abu-Raddad LJ, Chemaitelly H, Butt AA. Effectiveness of the BNT162b2 Covid-19 Vaccine against the
- 437 B.1.1.7 and B.1.351 Variants. N Engl J Med 2021; 385:187-9.
- 438 40. World Health Organization. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern.
- 439 Accessed 29 November 2021 2021.
- 440 41. d'Arminio Monforte A, Tavelli A, Perrone PM, et al. Association between previous infection with
- 441 SARS CoV-2 and the risk of self-reported symptoms after mRNA BNT162b2 vaccination: Data from 3,078
- 442 health care workers. EClinicalMedicine 2021; 36.
- 443 42. Menni C, Klaser K, May A, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in
- 444 users of the COVID Symptom Study app in the UK: a prospective observational study. The Lancet
- 445 Infectious Diseases 2021; 21:939-49.
- 446 43. Hwang YH, Song KH, Choi Y, et al. Can reactogenicity predict immunogenicity after COVID-19
- 447 vaccination? Korean J Intern Med 2021; 36:1486-91. 447 vaccination? Korean J Intern Med 2021; 36:1486-91.

- 448 44. Mathioudakis AG, Ghrew M, Ustianowski A, et al. Self-Reported Real-World Safety and
449 Reactogenicity of COVID-19 Vaccines: A Vaccine Recipient Survey. Life (Basel) 2021; 11.
-
- 450 45. Kennedy JL, Forrest JC, Young SG, et al. Temporal Variations in Seroprevalence of SARS-CoV-2
- 451 Infections by Race and Ethnicity in Arkansas. med Rxiv 2021:2021.07.15.21260213.
- 452 46. Rogawski McQuade ET, Guertin KA, Becker L, et al. Assessment of Seroprevalence of SARS-CoV-2 and
- 453 Risk Factors Associated With COVID-19 Infection Among Outpatients in Virginia. JAMA Network Open
- 453 Risk Factors Associated With COVID-19 Infection Among Outpatients in Virginia. JAMA Network Open
- 454 2021; 4:e2035234-e.
- 456 Monovalent Vaccines in HIV-Infected Children and Youth, Journal of the Pediatric Infectious Diseases
- 156 Monoralent Vacanis in HIV-Infectious inherities in Andrea Children and Youth. Journal of the Pediatric Infectious
457 Society 2013; 2:352-60.
- Society 2013; 2:352-60.
458 48. Arguedas A, Soley C, Lindert K. Responses to 2009 H1N1 Vaccine in Children 3 to 17 Years of Age.
- 459 New England Journal of Medicine 2010; 362:370-2.
- 460 49. Netea MG, Domínguez-Andrés J, Barreiro LB, et al. Defining trained immunity and its role in health
- 461 and disease. Nature Reviews Immunology 2020; 20:375-88.
- 462 50. Rydyznski Moderbacher C, Ramirez SI, Dan JM, et al. Antigen-Specific Adaptive Immunity to SARS-
- 463 CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity. Cell 2020; 183:996-1012.e19.
. . .

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2022.04.05.22273450;](https://doi.org/10.1101/2022.04.05.22273450) this version posted April 6, 2022. The copyright holder for this preprint

Figure 1: Antibody response following natural infection and vaccination

Each black point represents a sample from a participant, grey lines connect points from the same participant, and the grey shaded area represents the maximum number of days between doses relative to date of full vaccination (14 days after second dose, regardless of vaccine manufacturer). A) Days since e full vaccination vs. log titers over time. t=0 on the x-axis represents the day when COVID+ participants became fully vaccinated (2 weeks after second vaccination). Bi-phasic, generalized additive model (GAM) is visualized by a blue line. B) In unvaccinated COVID+ participants, log₂ antibody titers decay at a rate of -0.010 per day after last positive COVID-19 test result. Fitted linear model is visualized by a red line. Note that three points were excluded from the above figure due to the temporal scale used to graphically y depict the data but are included in the analyses herein. C) In vaccinated COVID+ participants, log_2

antibody titers decay at a rate of -0.015 per day after full vaccination. Fitted linear model is visualized by

a green line.

Figure 1: Symptoms experienced during infection significantly influences peak titer responses following full vaccination.

Number of symptoms during COVID-19 infection were positively correlated with peak log₂ COVID-19 antibody titers following full vaccination (Pearson's $r = 0.296$; $p = .041$)

Table 1: Characteristics of the Study Population Following Natural Infection, 1st Dose of Vaccine, and

2nd Dose of Vaccine

a Each count is the number of individuals who self-reported each symptom at the timepoint listed in

each column. Percentages are based on the total n for each column.

b All samples collected following natural infection were included for analysis.

Table 1: Symptoms Experienced by the Study Cohort Following Natural Infection, 1st Dose of Vaccine,

and 2nd Dose of Vaccine

^a All symptoms reported during SARS-CoV-2 Infection, as well as local and systemic symptoms following

vaccination were included in LASSO modeling as shown in Supplementary Table 1.

Table 1: Symptoms and demographic factors influence antibody responses following natural infection

and full vaccination

Four LASSO models and linear mixed-effects (LME) p-values were generated to assess the predictive

value of categorical and discrete variables while controlling for between-subjects' differences.

Significant categorical LASSO-generated variables underwent additional post-hoc Tukey to test for

directionality and to correct for multiple comparisons. A p-value <0.05 was considered statistically

significant.

a LME for predictors of main effects

f Post-hoc Tukey test for directionality of categorical variables due to significant main effects "